+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Protein Binding Assays - Global Strategic Business Report

  • PDF Icon

    Report

  • 193 Pages
  • November 2024
  • Region: Global
  • Global Industry Analysts, Inc
  • ID: 4805435
The global market for Protein Binding Assays was estimated at US$444.2 Million in 2023 and is projected to reach US$834.9 Million by 2030, growing at a CAGR of 9.4% from 2023 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions.

Global Protein Binding Assays Market - Key Trends and Drivers Summarized

Understanding the Complexities: The Expanding Market for Protein Binding Assays

Protein binding assays are crucial tools in drug discovery and development, providing essential insights into the interactions between drugs and their target proteins. These assays help researchers determine the binding affinity of a drug to a protein, which is critical for understanding its pharmacokinetics, pharmacodynamics, and overall efficacy. The pharmaceutical and biotechnology industries heavily rely on these assays during the early stages of drug development to screen potential drug candidates and optimize lead compounds. As the demand for personalized medicine grows, protein binding assays play an increasingly vital role in identifying and developing drugs tailored to specific patient populations, making them indispensable in modern healthcare.

How Are Technological Advancements Enhancing Assay Accuracy and Efficiency?

Technological advancements have significantly improved the accuracy, sensitivity, and efficiency of protein binding assays. The development of high-throughput screening (HTS) technologies has enabled the simultaneous analysis of thousands of compounds, accelerating the drug discovery process. Additionally, innovations in label-free detection methods, such as surface plasmon resonance (SPR) and isothermal titration calorimetry (ITC), have provided more precise measurements of binding interactions without the need for fluorescent or radioactive labels. These advancements have not only improved the reliability of the data generated by protein binding assays but have also reduced the time and cost associated with drug development. Furthermore, the integration of artificial intelligence (AI) and machine learning algorithms is enhancing the predictive capabilities of these assays, allowing for more accurate identification of potential drug candidates.

What Role Does Regulatory Compliance Play in the Market?

Regulatory compliance is a significant factor driving the adoption of advanced protein binding assays in the pharmaceutical and biotechnology industries. Regulatory agencies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) require comprehensive data on drug-protein interactions as part of the drug approval process. This has led to an increased demand for assays that provide accurate and reproducible results, ensuring that drugs are both safe and effective. The stringent requirements for drug approval have pushed companies to adopt the latest assay technologies and methodologies, further driving innovation in the field. Additionally, the growing focus on biosimilars and biologics, which require detailed characterization of protein binding properties, has further increased the demand for advanced protein binding assays.

What Are the Key Growth Drivers in the Market?

The growth in the protein binding assays market is driven by several factors. The increasing demand for personalized medicine and targeted therapies has spurred the need for more accurate and reliable protein binding assays. Technological advancements, such as the development of high-throughput screening technologies and label-free detection methods, have significantly improved the efficiency and accuracy of these assays, driving their adoption in drug discovery and development. Regulatory requirements for comprehensive data on drug-protein interactions have also played a crucial role in driving the market, as companies seek to ensure compliance with stringent safety and efficacy standards. Additionally, the growing focus on biologics and biosimilars, which require detailed protein characterization, is further propelling the demand for protein binding assays.

Key Insights:

  • Market Growth: Understand the significant growth trajectory of the Equilibrium Dialysis Technology segment, which is expected to reach US$342.2 Million by 2030 with a CAGR of a 9.6%. The Ultrafiltration Technology segment is also set to grow at 9.8% CAGR over the analysis period.
  • Regional Analysis: Gain insights into the U.S. market, estimated at $120.9 Million in 2023, and China, forecasted to grow at an impressive 8.7% CAGR to reach $127.7 Million by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.

Why You Should Buy This Report:

  • Detailed Market Analysis: Access a thorough analysis of the Global Protein Binding Assays Market, covering all major geographic regions and market segments.
  • Competitive Insights: Get an overview of the competitive landscape, including the market presence of major players across different geographies.
  • Future Trends and Drivers: Understand the key trends and drivers shaping the future of the Global Protein Binding Assays Market.
  • Actionable Insights: Benefit from actionable insights that can help you identify new revenue opportunities and make strategic business decisions.

Key Questions Answered:

  • How is the Global Protein Binding Assays Market expected to evolve by 2030?
  • What are the main drivers and restraints affecting the market?
  • Which market segments will grow the most over the forecast period?
  • How will market shares for different regions and segments change by 2030?
  • Who are the leading players in the market, and what are their prospects?

Report Features:

  • Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2023 to 2030.
  • In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
  • Company Profiles: Coverage of major players such as Absorption Systems LLC, ADMEcell, Inc., Biotium, Inc., and more.
  • Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.

Select Competitors (Total 44 Featured):

  • Absorption Systems LLC
  • ADMEcell, Inc.
  • Biotium, Inc.
  • Danaher Corporation
  • Eurofins Scientific
  • GE Healthcare Life Sciences
  • HTDialysis, LLC
  • Merck & Co., Inc.
  • Sovicell GmbH
  • Thermo Fisher Scientific, Inc.

Table of Contents

I. METHODOLOGYII. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Protein Binding Assays - Global Key Competitors Percentage Market Share in 2024 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
  • Global Economic Update
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
  • Rising Demand in Drug Discovery and Development Propels Market Growth
  • Increasing Use in Pharmacokinetics Expands Addressable Market Opportunity
  • Technological Advancements in High-Throughput Screening Strengthen Market Position
  • Growing Focus on Personalized Medicine Drives Adoption of Protein Binding Assays
  • Surge in Demand for Accurate and Reliable Assay Technologies Generates New Opportunities
  • Development of Novel Assay Formats Sustains Market Growth
  • Expanding Applications in Toxicology Testing Throws Spotlight on Market Potential
  • Surge in Demand for Assays in Biologics Development Expands Market Horizons
  • Growing Awareness of Drug-Protein Interactions Drives Market Adoption
  • Innovations in Label-Free Detection Technologies Generate New Market Opportunities
  • Rising Use of Protein Binding Assays in Clinical research Throws Spotlight on Market Dynamics
4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Recent Past, Current & Future Analysis for Protein Binding Assays by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • TABLE 2: World 7-Year Perspective for Protein Binding Assays by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2024 & 2030
  • TABLE 3: World Recent Past, Current & Future Analysis for Equilibrium Dialysis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • TABLE 4: World 7-Year Perspective for Equilibrium Dialysis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
  • TABLE 5: World Recent Past, Current & Future Analysis for Ultrafiltration by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • TABLE 6: World 7-Year Perspective for Ultrafiltration by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
  • TABLE 7: World Recent Past, Current & Future Analysis for Ultracentrifugation by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • TABLE 8: World 7-Year Perspective for Ultracentrifugation by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
  • TABLE 9: World Protein Binding Assays Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
  • TABLE 10: World Recent Past, Current & Future Analysis for Other Technologies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • TABLE 11: World 7-Year Perspective for Other Technologies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
  • TABLE 12: World Recent Past, Current & Future Analysis for Pharma & Biotech Companies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • TABLE 13: World 7-Year Perspective for Pharma & Biotech Companies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
  • TABLE 14: World Recent Past, Current & Future Analysis for Contract Research Organizations by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • TABLE 15: World 7-Year Perspective for Contract Research Organizations by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
  • TABLE 16: World Recent Past, Current & Future Analysis for Research & Diagnostic Laboratories by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • TABLE 17: World 7-Year Perspective for Research & Diagnostic Laboratories by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
III. MARKET ANALYSIS
UNITED STATES
  • Protein Binding Assays Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
  • TABLE 18: USA Recent Past, Current & Future Analysis for Protein Binding Assays by Technology - Equilibrium Dialysis, Ultrafiltration, Ultracentrifugation and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 19: USA 7-Year Perspective for Protein Binding Assays by Technology - Percentage Breakdown of Value Sales for Equilibrium Dialysis, Ultrafiltration, Ultracentrifugation and Other Technologies for the Years 2024 & 2030
  • TABLE 20: USA Recent Past, Current & Future Analysis for Protein Binding Assays by End-Use - Pharma & Biotech Companies, Contract Research Organizations and Research & Diagnostic Laboratories - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 21: USA 7-Year Perspective for Protein Binding Assays by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Contract Research Organizations and Research & Diagnostic Laboratories for the Years 2024 & 2030
CANADA
  • TABLE 22: Canada Recent Past, Current & Future Analysis for Protein Binding Assays by Technology - Equilibrium Dialysis, Ultrafiltration, Ultracentrifugation and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 23: Canada 7-Year Perspective for Protein Binding Assays by Technology - Percentage Breakdown of Value Sales for Equilibrium Dialysis, Ultrafiltration, Ultracentrifugation and Other Technologies for the Years 2024 & 2030
  • TABLE 24: Canada Recent Past, Current & Future Analysis for Protein Binding Assays by End-Use - Pharma & Biotech Companies, Contract Research Organizations and Research & Diagnostic Laboratories - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 25: Canada 7-Year Perspective for Protein Binding Assays by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Contract Research Organizations and Research & Diagnostic Laboratories for the Years 2024 & 2030
JAPAN
  • Protein Binding Assays Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
  • TABLE 26: Japan Recent Past, Current & Future Analysis for Protein Binding Assays by Technology - Equilibrium Dialysis, Ultrafiltration, Ultracentrifugation and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 27: Japan 7-Year Perspective for Protein Binding Assays by Technology - Percentage Breakdown of Value Sales for Equilibrium Dialysis, Ultrafiltration, Ultracentrifugation and Other Technologies for the Years 2024 & 2030
  • TABLE 28: Japan Recent Past, Current & Future Analysis for Protein Binding Assays by End-Use - Pharma & Biotech Companies, Contract Research Organizations and Research & Diagnostic Laboratories - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 29: Japan 7-Year Perspective for Protein Binding Assays by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Contract Research Organizations and Research & Diagnostic Laboratories for the Years 2024 & 2030
CHINA
  • Protein Binding Assays Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
  • TABLE 30: China Recent Past, Current & Future Analysis for Protein Binding Assays by Technology - Equilibrium Dialysis, Ultrafiltration, Ultracentrifugation and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 31: China 7-Year Perspective for Protein Binding Assays by Technology - Percentage Breakdown of Value Sales for Equilibrium Dialysis, Ultrafiltration, Ultracentrifugation and Other Technologies for the Years 2024 & 2030
  • TABLE 32: China Recent Past, Current & Future Analysis for Protein Binding Assays by End-Use - Pharma & Biotech Companies, Contract Research Organizations and Research & Diagnostic Laboratories - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 33: China 7-Year Perspective for Protein Binding Assays by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Contract Research Organizations and Research & Diagnostic Laboratories for the Years 2024 & 2030
EUROPE
  • Protein Binding Assays Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
  • TABLE 34: Europe Recent Past, Current & Future Analysis for Protein Binding Assays by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • TABLE 35: Europe 7-Year Perspective for Protein Binding Assays by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2024 & 2030
  • TABLE 36: Europe Recent Past, Current & Future Analysis for Protein Binding Assays by Technology - Equilibrium Dialysis, Ultrafiltration, Ultracentrifugation and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 37: Europe 7-Year Perspective for Protein Binding Assays by Technology - Percentage Breakdown of Value Sales for Equilibrium Dialysis, Ultrafiltration, Ultracentrifugation and Other Technologies for the Years 2024 & 2030
  • TABLE 38: Europe Recent Past, Current & Future Analysis for Protein Binding Assays by End-Use - Pharma & Biotech Companies, Contract Research Organizations and Research & Diagnostic Laboratories - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 39: Europe 7-Year Perspective for Protein Binding Assays by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Contract Research Organizations and Research & Diagnostic Laboratories for the Years 2024 & 2030
FRANCE
  • Protein Binding Assays Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
  • TABLE 40: France Recent Past, Current & Future Analysis for Protein Binding Assays by Technology - Equilibrium Dialysis, Ultrafiltration, Ultracentrifugation and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 41: France 7-Year Perspective for Protein Binding Assays by Technology - Percentage Breakdown of Value Sales for Equilibrium Dialysis, Ultrafiltration, Ultracentrifugation and Other Technologies for the Years 2024 & 2030
  • TABLE 42: France Recent Past, Current & Future Analysis for Protein Binding Assays by End-Use - Pharma & Biotech Companies, Contract Research Organizations and Research & Diagnostic Laboratories - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 43: France 7-Year Perspective for Protein Binding Assays by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Contract Research Organizations and Research & Diagnostic Laboratories for the Years 2024 & 2030
GERMANY
  • Protein Binding Assays Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
  • TABLE 44: Germany Recent Past, Current & Future Analysis for Protein Binding Assays by Technology - Equilibrium Dialysis, Ultrafiltration, Ultracentrifugation and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 45: Germany 7-Year Perspective for Protein Binding Assays by Technology - Percentage Breakdown of Value Sales for Equilibrium Dialysis, Ultrafiltration, Ultracentrifugation and Other Technologies for the Years 2024 & 2030
  • TABLE 46: Germany Recent Past, Current & Future Analysis for Protein Binding Assays by End-Use - Pharma & Biotech Companies, Contract Research Organizations and Research & Diagnostic Laboratories - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 47: Germany 7-Year Perspective for Protein Binding Assays by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Contract Research Organizations and Research & Diagnostic Laboratories for the Years 2024 & 2030
ITALY
  • TABLE 48: Italy Recent Past, Current & Future Analysis for Protein Binding Assays by Technology - Equilibrium Dialysis, Ultrafiltration, Ultracentrifugation and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 49: Italy 7-Year Perspective for Protein Binding Assays by Technology - Percentage Breakdown of Value Sales for Equilibrium Dialysis, Ultrafiltration, Ultracentrifugation and Other Technologies for the Years 2024 & 2030
  • TABLE 50: Italy Recent Past, Current & Future Analysis for Protein Binding Assays by End-Use - Pharma & Biotech Companies, Contract Research Organizations and Research & Diagnostic Laboratories - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 51: Italy 7-Year Perspective for Protein Binding Assays by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Contract Research Organizations and Research & Diagnostic Laboratories for the Years 2024 & 2030
UNITED KINGDOM
  • Protein Binding Assays Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
  • TABLE 52: UK Recent Past, Current & Future Analysis for Protein Binding Assays by Technology - Equilibrium Dialysis, Ultrafiltration, Ultracentrifugation and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 53: UK 7-Year Perspective for Protein Binding Assays by Technology - Percentage Breakdown of Value Sales for Equilibrium Dialysis, Ultrafiltration, Ultracentrifugation and Other Technologies for the Years 2024 & 2030
  • TABLE 54: UK Recent Past, Current & Future Analysis for Protein Binding Assays by End-Use - Pharma & Biotech Companies, Contract Research Organizations and Research & Diagnostic Laboratories - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 55: UK 7-Year Perspective for Protein Binding Assays by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Contract Research Organizations and Research & Diagnostic Laboratories for the Years 2024 & 2030
REST OF EUROPE
  • TABLE 56: Rest of Europe Recent Past, Current & Future Analysis for Protein Binding Assays by Technology - Equilibrium Dialysis, Ultrafiltration, Ultracentrifugation and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 57: Rest of Europe 7-Year Perspective for Protein Binding Assays by Technology - Percentage Breakdown of Value Sales for Equilibrium Dialysis, Ultrafiltration, Ultracentrifugation and Other Technologies for the Years 2024 & 2030
  • TABLE 58: Rest of Europe Recent Past, Current & Future Analysis for Protein Binding Assays by End-Use - Pharma & Biotech Companies, Contract Research Organizations and Research & Diagnostic Laboratories - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 59: Rest of Europe 7-Year Perspective for Protein Binding Assays by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Contract Research Organizations and Research & Diagnostic Laboratories for the Years 2024 & 2030
ASIA-PACIFIC
  • Protein Binding Assays Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
  • TABLE 60: Asia-Pacific Recent Past, Current & Future Analysis for Protein Binding Assays by Technology - Equilibrium Dialysis, Ultrafiltration, Ultracentrifugation and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 61: Asia-Pacific 7-Year Perspective for Protein Binding Assays by Technology - Percentage Breakdown of Value Sales for Equilibrium Dialysis, Ultrafiltration, Ultracentrifugation and Other Technologies for the Years 2024 & 2030
  • TABLE 62: Asia-Pacific Recent Past, Current & Future Analysis for Protein Binding Assays by End-Use - Pharma & Biotech Companies, Contract Research Organizations and Research & Diagnostic Laboratories - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 63: Asia-Pacific 7-Year Perspective for Protein Binding Assays by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Contract Research Organizations and Research & Diagnostic Laboratories for the Years 2024 & 2030
REST OF WORLD
  • TABLE 64: Rest of World Recent Past, Current & Future Analysis for Protein Binding Assays by Technology - Equilibrium Dialysis, Ultrafiltration, Ultracentrifugation and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 65: Rest of World 7-Year Perspective for Protein Binding Assays by Technology - Percentage Breakdown of Value Sales for Equilibrium Dialysis, Ultrafiltration, Ultracentrifugation and Other Technologies for the Years 2024 & 2030
  • TABLE 66: Rest of World Recent Past, Current & Future Analysis for Protein Binding Assays by End-Use - Pharma & Biotech Companies, Contract Research Organizations and Research & Diagnostic Laboratories - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 67: Rest of World 7-Year Perspective for Protein Binding Assays by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Contract Research Organizations and Research & Diagnostic Laboratories for the Years 2024 & 2030
IV. COMPETITION

Companies Mentioned

  • Absorption Systems LLC
  • ADMEcell, Inc.
  • Biotium, Inc.
  • Danaher Corporation
  • Eurofins Scientific
  • GE Healthcare Life Sciences
  • HTDialysis, LLC
  • Merck & Co., Inc.
  • Sovicell GmbH
  • Thermo Fisher Scientific, Inc.

Table Information